These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31300450)

  • 1. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
    Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
    Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
    Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.
    Qian Y; Chai S; Liang Z; Wang Y; Zhou Y; Xu X; Zhang C; Zhang M; Si J; Huang F; Huang Z; Hong W; Wang K
    Mol Cancer; 2014 Jul; 13():176. PubMed ID: 25047660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
    Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
    Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
    [No Abstract]   [Full Text] [Related]  

  • 15. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
    Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET rearrangements are actionable alterations in breast cancer.
    Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
    Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
    Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
    Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H
    Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.